| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | John D. Lambris | Q6228220 |
| Markus S Huber-Lang | Q59692242 | ||
| Bo Nilsson | Q42768789 | ||
| George Hajishengallis | Q39672238 | ||
| P2093 | author name string | Daniel Ricklin | |
| Florea Lupu | |||
| Antonio M Risitano | |||
| Dimitrios C Mastellos | |||
| Petros Kokkinos | |||
| Despina Yancopoulou | |||
| Ali R Biglarnia | |||
| P2860 | cites work | A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration | Q24523983 |
| Complement factor H polymorphism in age-related macular degeneration | Q24553334 | ||
| Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement | Q24594632 | ||
| The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss | Q24618908 | ||
| Compstatin: a complement inhibitor on its way to clinical application | Q24658454 | ||
| The inflammatory response in sepsis | Q26849300 | ||
| Complement and dysbiosis in periodontal disease | Q26862615 | ||
| Genetic variants in the complement system predisposing to age-related macular degeneration: a review | Q27021836 | ||
| Is asthma related to choroidal neovascularization? | Q27304489 | ||
| Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition | Q27647015 | ||
| Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor | Q27655786 | ||
| Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by Staphylococcus aureus in a human whole blood model. | Q52647705 | ||
| Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. | Q53552266 | ||
| Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. | Q54014234 | ||
| Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin | Q58523879 | ||
| Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts | Q58524435 | ||
| The third component of complement (C3) is responsible for the intracellular survival of Leishmania major | Q59096916 | ||
| MS-325: albumin-targeted contrast agent for MR angiography | Q74521655 | ||
| Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation | Q82661695 | ||
| Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation | Q84420087 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Complement--tapping into new sites and effector systems | Q85959086 | ||
| Complement factor H variant increases the risk of age-related macular degeneration | Q28239239 | ||
| Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach | Q28244196 | ||
| Structure of C3b in complex with CRIg gives insights into regulation of complement activation | Q28269302 | ||
| Structure of C3b reveals conformational changes that underlie complement activity | Q28269312 | ||
| Structures of complement component C3 provide insights into the function and evolution of immunity | Q28273530 | ||
| The future of peptide-based drugs | Q28281702 | ||
| Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response | Q28658053 | ||
| Complement factor H polymorphism and age-related macular degeneration | Q29614931 | ||
| Complement: a key system for immune surveillance and homeostasis | Q29615484 | ||
| Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis | Q30582298 | ||
| New approaches in data integration for systems chemical biology | Q30610758 | ||
| Studies of structure-activity relations of complement inhibitor compstatin. | Q31152002 | ||
| N-methylation of peptides: a new perspective in medicinal chemistry | Q33352771 | ||
| Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis | Q33389544 | ||
| Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis | Q33807749 | ||
| Systemic lupus erythematosus, complement deficiency, and apoptosis | Q34082803 | ||
| Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin | Q34254555 | ||
| Complement-targeted therapeutics | Q34255011 | ||
| Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants | Q34303850 | ||
| Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency | Q34459360 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria | Q34576112 | ||
| Role of complement in host-microbe homeostasis of the periodontium | Q34727808 | ||
| Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells | Q34760201 | ||
| Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis | Q34911214 | ||
| Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration | Q35064666 | ||
| Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin | Q35109329 | ||
| Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters | Q35164180 | ||
| The role of complement in tumor growth | Q35231345 | ||
| Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood | Q35247803 | ||
| Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape | Q35252156 | ||
| Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium | Q35252177 | ||
| Synthetic small-molecule complement inhibitors. | Q35968800 | ||
| Complement-targeted therapeutics in periodontitis | Q36302901 | ||
| In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation | Q39675757 | ||
| Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice | Q39729995 | ||
| Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization | Q40107597 | ||
| Complement deficiency and immune complex disease | Q40737580 | ||
| Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab | Q42788929 | ||
| Microbial hijacking of complement-toll-like receptor crosstalk | Q42911622 | ||
| Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation | Q43239952 | ||
| The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood | Q43475073 | ||
| Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin | Q43506199 | ||
| Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation | Q44102024 | ||
| C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood | Q44198286 | ||
| Albumin binding as a general strategy for improving the pharmacokinetics of proteins | Q44209151 | ||
| Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. | Q46241811 | ||
| N-methylation of N(alpha)-acylated, fully C(alpha)-methylated, linear, folded peptides: synthetic and conformational aspects. | Q52571729 | ||
| The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. | Q52625214 | ||
| Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. | Q36405585 | ||
| Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist | Q36417215 | ||
| New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties | Q36456593 | ||
| Progress and Trends in Complement Therapeutics | Q36479278 | ||
| Complement in immune and inflammatory disorders: pathophysiological mechanisms | Q36756850 | ||
| Complement in immune and inflammatory disorders: therapeutic interventions | Q36756854 | ||
| Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. | Q36813033 | ||
| CMAP: Complement Map Database | Q36984979 | ||
| Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood | Q37075440 | ||
| Complexity of complement activation in sepsis | Q37170093 | ||
| Soluble CR1 therapy improves complement regulation in C3 glomerulopathy | Q37260204 | ||
| Dense deposit disease and C3 glomerulopathy | Q37286653 | ||
| Rational engineering of a minimized immune inhibitor with unique triple-targeting properties | Q37300691 | ||
| Recent developments in low molecular weight complement inhibitors | Q37456835 | ||
| Inflammation and the pathogenesis of age-related macular degeneration. | Q37489920 | ||
| C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens | Q37543817 | ||
| Synthetic therapeutic peptides: science and market | Q37625355 | ||
| Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria | Q37670073 | ||
| PEGylation of therapeutic proteins | Q37673091 | ||
| Mesenchymal stem cells infected with Mycoplasma arginini secrete complement C3 to regulate immunoglobulin production in B lymphocytes | Q37726116 | ||
| Antimicrobial prophylaxis regimens following transplantation | Q37889599 | ||
| Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood | Q37938954 | ||
| Therapeutic targeting of the complement system in age-related macular degeneration: a review. | Q37981256 | ||
| The role of complement in the early immune response to transplantation. | Q38013049 | ||
| Regulation of humoral immunity by complement | Q38037801 | ||
| The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases | Q38042219 | ||
| Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders | Q38042220 | ||
| The role of complement in antibody-mediated rejection in kidney transplantation | Q38048605 | ||
| Pain in end-stage renal disease: a frequent and neglected clinical problem. | Q38068258 | ||
| Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies | Q38080869 | ||
| PEGylated drugs in rheumatology--why develop them and do they work? | Q38130374 | ||
| Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition | Q38156229 | ||
| Complement modulation in solid-organ transplantation. | Q38226479 | ||
| Antibody-mediated rejection despite inhibition of terminal complement. | Q38427447 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 423-440 | |
| P577 | publication date | 2015-03-09 | |
| P1433 | published in | European Journal of Clinical Investigation | Q15745208 |
| P1476 | title | Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention | |
| P478 | volume | 45 |
| Q55255568 | A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. |
| Q92222061 | A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates |
| Q52370165 | A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. |
| Q37040241 | A previously unrecognized role of C3a in proteinuric progressive nephropathy |
| Q53100671 | Adding Functions to Biomaterial Surfaces through Protein Incorporation. |
| Q93147350 | Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT |
| Q36315497 | Applying complement therapeutics to rare diseases. |
| Q92305390 | Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy |
| Q52429262 | Changes in extracellular matrix cause RPE cells to make basal deposits and activate the alternative complement pathway. |
| Q37097826 | Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation |
| Q92035579 | Clinical promise of next-generation complement therapeutics |
| Q57492399 | Complement After Trauma: Suturing Innate and Adaptive Immunity |
| Q38817075 | Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood. |
| Q39246952 | Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. |
| Q38573616 | Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective |
| Q26797414 | Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches |
| Q28263460 | Complement System Part II: Role in Immunity |
| Q38849729 | Complement and Antibody-mediated Enhancement of Red Blood Cell Invasion and Growth of Malaria Parasites |
| Q38558926 | Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense |
| Q64094847 | Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics |
| Q37180462 | Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application |
| Q92603688 | Complement system and age-related macular degeneration: drugs and challenges |
| Q36460034 | Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention |
| Q38614302 | Complement, a target for therapy in inflammatory and degenerative diseases. |
| Q64102307 | Complement-Dependent Mechanisms and Interventions in Periodontal Disease |
| Q30276082 | Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia |
| Q35877192 | Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy |
| Q28077955 | Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets |
| Q28070056 | Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances |
| Q60998516 | Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma |
| Q64286847 | Evidence for the important role of inflammation in xenotransplantation |
| Q90390392 | Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
| Q49439487 | Expanding horizons in complement drug discovery: challenges and emerging strategies |
| Q38879877 | From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. |
| Q88867158 | Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis |
| Q46433084 | Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. |
| Q48371887 | Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways |
| Q36309711 | Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics. |
| Q95840971 | Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage |
| Q26752716 | Inflammogenesis of Secondary Spinal Cord Injury |
| Q36717275 | Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3 |
| Q58566667 | Interpretation of Serological Complement Biomarkers in Disease |
| Q64122298 | Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment |
| Q50199037 | Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. |
| Q33602320 | New milestones ahead in complement-targeted therapy |
| Q90116210 | Novel insights into the treatment of complement-mediated hemolytic anemias |
| Q47396517 | Novel mechanisms and functions of complement. |
| Q35925245 | Phosphoserine Lyase Deoxyribozymes: DNA-Catalyzed Formation of Dehydroalanine Residues in Peptides. |
| Q41001928 | Porphyromonas gingivalis disturbs host-commensal homeostasis by changing complement function |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q89080771 | Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily |
| Q57101626 | Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock |
| Q47331810 | Reduced order modeling and analysis of the human complement system |
| Q41566679 | Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. |
| Q58522423 | Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen |
| Q92364779 | Targeting the complement system in bacterial meningitis |
| Q64905140 | The Challenges and Promise of Complement Therapeutics for Ocular Diseases. |
| Q90733072 | The Complement System Is Essential for the Phagocytosis of Mesenchymal Stromal Cells by Monocytes |
| Q48241051 | The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential |
| Q28070153 | The complement system: an evolution in progress |
| Q94491636 | The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |
| Q58115660 | The multifaceted role of complement in kidney transplantation |
| Q36643354 | The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation |
| Q47336749 | The renaissance of complement therapeutics. |
| Q36363005 | Therapeutic control of complement activation at the level of the central component C3. |
| Q38721559 | Therapeutic options in neuromyelitis optica spectrum disorders |
| Q36668896 | Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. |
| Q38995165 | Viral-derived complement inhibitors: current status and potential role in immunomodulation |
| Q59223627 | Virtual Screening of Chemical Compounds for Discovery of Complement C3 Ligands |
Search more.